Subscribe

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)

CNY15.76 +0.64 (+4.23%)
CN SHZ Healthcare Biotechnology
Address No. 333, Huiquan Road 344000
Fuzhou, CN
CEO Yuxuan Pan
Website china-boya.com
IPO 2012-03-08
ISIN CNE100001FF1

Explore sections of this company profile

Description

Established in 1993 and headquartered in Fuzhou, China, China Resources Boya Bio-pharmaceutical Group Co., Ltd. (formerly Boya Bio-pharmaceutical Group Co., Ltd.) is a comprehensive pharmaceutical enterprise operating across China. The company is engaged in the research, development, production, and sale of a diverse portfolio, primarily focusing on blood products, diabetes medications, and various biochemical and chemical pharmaceuticals. Its extensive range of blood-derived products includes human fibrinogen, human albumin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, and freeze-dried intravenous human immunoglobulin. For diabetes management, the company offers metformin hydrochloride (both tablets and enteric-coated versions), pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Additionally, it produces specialized injections such as compound osteotide, oxytocin, and heparin sodium, which are utilized across numerous medical fields, including general medicine, hepatitis treatment, gynecology, and immunomodulatory applications.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY15.76 +0.64 (+4.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.17
Float Shares
329.46M
Free Float %
65.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+7.15% +5.17% -5.66% -25.89% -30.63% -27.04% -38.49% -55.31% -56.24% -57.34% +91.30%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
15.76
DCF (Unlevered) 19.24 +22.1%
DCF (Levered) 20.77 +31.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 75% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 2 +1
Hold 1 -1
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
6.51
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +18.2% ★ Q1'26: -40.1% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -72.2% Q1'26: -78.6% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -4.9% Q1'26: -90.3% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    +13.2% ★ Q1'26: +4.1% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    +5.9% ★ Q1'26: +0.9% (vs Q1'25)
  • ✓
    Share dilution Biotechnology: -3.4%
    +0.0% ★ Q1'26: +1.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.77× ★ Q1'26: 4.18× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.22) × ERP
WACC = 96% × Ke + 4% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 19.24 Current price: 15.76
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
4 Rev. Ana.
1 EPS Ana. 		Dec 2027
3 Rev. Ana.
1 EPS Ana. 		Dec 2028
2 Rev. Ana.
2 EPS Ana.
Revenue
543.18M
est: 548.00M (-0.9%)
946.60M
est: 987.30M (-4.1%)
1.39B
est: 1.36B (+2.2%)
2.39B
est: 2.54B (-5.9%)
2.91B
est: 2.91B (-0.1%)
2.51B
est: 2.77B (-9.4%)
2.65B
est: 2.80B (-5.3%)
2.76B
est: 2.80B (-1.5%)
2.65B
est: 2.01B (+32.1%)
1.73B
est: 1.78B (-2.7%)
2.05B
est: 1.98B (+3.3%)
2.03B
1.81B – 2.17B
+2.3% YoY
2.08B
1.87B – 2.39B
+2.7% YoY
2.22B
2.20B – 2.24B
+6.5% YoY
EBITDA
192.08M
est: 121.56M (+58.0%)
359.16M
est: 219.00M (+64.0%)
449.37M
est: 301.83M (+48.9%)
608.32M
est: 563.10M (+8.0%)
605.49M
est: 645.64M (-6.2%)
411.52M
est: 615.34M (-33.1%)
510.65M
est: 620.55M (-17.7%)
600.38M
est: 621.18M (-3.3%)
624.38M
est: 464.49M (+34.4%)
519.84M
est: 412.81M (+25.9%)
434.36M
est: 459.06M (-5.4%)
469.69M
419.34M – 502.25M
+2.3% YoY
482.41M
433.44M – 552.65M
+2.7% YoY
513.60M
508.04M – 519.16M
+6.5% YoY
EBIT
162.13M
est: 100.23M (+61.8%)
314.80M
est: 180.58M (+74.3%)
403.68M
est: 248.88M (+62.2%)
554.06M
est: 464.31M (+19.3%)
522.72M
est: 532.38M (-1.8%)
330.18M
est: 507.39M (-34.9%)
414.49M
est: 511.68M (-19.0%)
507.16M
est: 512.20M (-1.0%)
529.38M
est: 367.13M (+44.2%)
422.12M
est: 326.29M (+29.4%)
269.66M
est: 362.85M (-25.7%)
371.25M
331.45M – 396.98M
+2.3% YoY
381.30M
342.60M – 436.82M
+2.7% YoY
405.95M
401.56M – 410.35M
+6.5% YoY
Net Income
151.80M
est: 194.98M (-22.1%)
272.04M
est: 340.68M (-20.1%)
356.59M
est: 449.22M (-20.6%)
469.17M
est: 538.74M (-12.9%)
426.15M
est: 597.87M (-28.7%)
260.06M
est: 456.35M (-43.0%)
344.53M
est: 509.29M (-32.4%)
432.20M
est: 468.95M (-7.8%)
237.47M
est: 227.52M (+4.4%)
396.99M
est: 516.99M (-23.2%)
112.70M
est: 374.15M (-69.9%)
336.50M
287.69M – 379.72M
-10.1% YoY
370.00M
326.92M – 431.50M
+10.0% YoY
426.50M
419.01M – 460.40M
+15.3% YoY
SGA
177.70M
est: 192.16M (-7.5%)
267.84M
est: 346.21M (-22.6%)
503.64M
est: 477.14M (+5.6%)
881.49M
est: 890.16M (-1.0%)
1.14B
est: 1.02B (+11.5%)
1.04B
est: 972.74M (+6.7%)
968.84M
est: 980.98M (-1.2%)
923.64M
est: 981.97M (-5.9%)
774.71M
est: 655.11M (+18.3%)
603.65M
est: 582.23M (+3.7%)
598.11M
est: 647.46M (-7.6%)
662.45M
591.43M – 708.38M
+2.3% YoY
680.38M
611.33M – 779.46M
+2.7% YoY
724.38M
716.54M – 732.22M
+6.5% YoY
EPS
0.44
est: 0.39 (+13.8%)
1.02
est: 0.68 (+51.0%)
0.89
est: 0.89 (-0.1%)
1.11
est: 1.07 (+3.9%)
1.00
est: 1.19 (-15.7%)
0.61
est: 0.91 (-32.6%)
0.79
est: 1.01 (-21.8%)
0.86
est: 0.93 (-7.5%)
0.47
est: 0.45 (+4.4%)
0.79
est: 1.02 (-22.7%)
0.22
est: 0.74 (-70.3%)
0.66
0.57 – 0.75
-10.8% YoY
0.75
0.65 – 0.86
+13.6% YoY
0.87
0.83 – 0.91
+16.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-28 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-27 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-26 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-25 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-22 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-21 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-20 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-19 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-18 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-15 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-14 B+ 3/5 4/5 3/5 4/5 3/5 1/5 4/5
2026-05-13 B+ 3/5 4/5 3/5 3/5 3/5 1/5 4/5
2026-05-12 B+ 3/5 4/5 3/5 3/5 3/5 1/5 4/5
2026-05-11 B 3/5 4/5 2/5 3/5 3/5 1/5 4/5
2026-05-08 B 3/5 4/5 2/5 3/5 3/5 1/5 4/5
2026-05-07 B 3/5 4/5 2/5 3/5 3/5 1/5 4/5
2026-05-06 B 3/5 4/5 2/5 3/5 3/5 1/5 4/5
2026-04-30 B 3/5 4/5 2/5 3/5 3/5 1/5 4/5
2026-04-29 B+ 3/5 4/5 2/5 4/5 3/5 1/5 4/5
2026-04-28 B+ 3/5 4/5 2/5 4/5 3/5 1/5 4/5
2026-04-27 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-24 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-23 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-22 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-21 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-20 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-17 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5
2026-04-16 B 3/5 4/5 2/5 4/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-567.76M
OE per share TTM
-1.13
Owner's Yield
-6.83%
Maintenance CapEx ratio
894.94%
Maint CapEx / Avg PPE
38.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 23 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Franklin FTSE China UCITS ETF FLXC.L 0.00% 66.3K 0.19%
2 Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX 0.00% 10.0K 0.40%
3 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 135.8K 0.39%
4 Schwab Emerging Markets Equity ETF SCHE 0.00% 124.9K 0.06%
5 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 74.9K 0.29%
6 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 9.7K 0.48%
7 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 22.0K 0.26%
8 Vanguard FTSE Emerging Markets ETF VWO 0.00% 1.08M 0.06%
9 Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L 0.00% 24.3K 0.17%
10 Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L 0.00% 24.3K 0.17%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
139.1K
Shares Outstanding
504.25M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Qingsong Lin Vice President — male
Shousun Ii Vice President — male
Shuanhong Zhang Vice President — male
Yuxuan Pan CFO, Board Secretary & Director — male
Zi He Wang Accounting Supervisor — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology